The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has spread before treatment, detecting recurrence in patients with rising ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

Diagnostic imaging plays an important role in identifying cancerous areas, which may help guide treatment decisions. Trofolastat is combined with the radioactive tracer technetium-99m to form ...

Trofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion detection.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...